Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019.

Autor: Lythgoe MP; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, W12 0HS, London, UK. Electronic address: M.Lythgoe@imperial.ac.uk., Krell J; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, W12 0HS, London, UK., Mahmoud S; Cancer Services, Imperial College Healthcare NHS Trust, London, W6 8RF, UK., Mills EC; Department of Oncology, Brighton & Sussex University Hospital NHS Trust, Brighton, BN2 5BE, UK., Vasudevan A; Department of Oncology, Brighton & Sussex University Hospital NHS Trust, Brighton, BN2 5BE, UK., Savage P; Department of Oncology, Brighton & Sussex University Hospital NHS Trust, Brighton, BN2 5BE, UK.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2021 Feb; Vol. 26 (2), pp. 301-307. Date of Electronic Publication: 2020 Nov 16.
DOI: 10.1016/j.drudis.2020.11.011
Abstrakt: Analysis of new anticancer drugs licensed in the UK found that 44 new therapies were approved from 2015 to 2019. No other 5-year period has produced as many new therapies. Most new drugs are kinase inhibitors (KIs, N=18) and monoclonal antibodies (mAbs, N=16) with only one classical cytotoxic chemotherapy (CC) licensed. The average median treatment duration has risen by 55 days to 318 days (263 days in 2010-2014). Drug costs have escalated; an average treatment course now costs £62 343, compared to £35 383 in 2010-2014. New drugs are delivering significant clinical benefits with longer treatment durations. However, the financial burden is greater, heralding economic challenges for healthcare providers.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: